NF-κB-dependent induction of cathelicidin-related antimicrobial peptide in murine mast cells by lipopolysaccharide

International Archives of Allergy and Immunology

Volumn 150, Issue 2, 2009, Pages 122-132

  Li, Guiming ^a   Domenico, Joanne ^a   Jia, Yi ^a   Lucas, Joseph J ^a   Gelfand, Erwin W ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

Cathelicidin related antimicrobial peptide; Inflammation; Mast cells; Transcription factors

Indexed keywords

CATHELICIDIN; CATHELICIDIN RELATED ANTIMICROBIAL PEPTIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYPEPTIDE ANTIBIOTIC AGENT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE; I KAPPA B; MAP3K2 PROTEIN, MOUSE; MAP3K3 PROTEIN, MOUSE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; STRESS ACTIVATED PROTEIN KINASE; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ARTICLE; BONE MARROW; CELL CULTURE; ENZYME INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; IMMUNOBLOTTING; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; C57BL MOUSE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BONE MARROW CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENE EXPRESSION REGULATION; I-KAPPA B PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MAP KINASE KINASE KINASE 2; MAP KINASE KINASE KINASE 3; MAST CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TRANSFECTION;

EID: 65549101141     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218115     Document Type: Article

References (58)

1. Tkacyzk C, Gilfillan AM: FcεRI-dependent signaling pathways in human mast cells. Clin Immunol 2001; 99: 198-210.
2. Blank U, Rivera J: The ins and outs of IgE-dependent mast cell exocytosis. Trends Immunol 2004; 25: 266-273.
3. Garrington TP, Ishizuka T, Papst PJ, Chaya-ma K, Webb S, Yujiri T, Sun W, Sather S, Russell DM, Gibson SB, Keller G, Gelfand EW, Johnson GL: MEKK2 gene disruption causes loss of cytokine production in response to IgE and c-Kit ligand stimulation of ES cell-derived mast cells. EMBO J 2000; 19: 5387-5395.
4. Chayama K, Papst PJ, Garrington TP, Pratt JC, Ishizuka T, Webb S, Ganiatsas S, Zon LI, Sun W, Johnson GL, Gelfand EW: Role of MEKK2-MEK5 in the regulation of TNF-α gene expression and MEKK2-MKK7 in the activation of c-Jun N-terminal kinase in mast cells. Proc Natl Acad Sci USA 2001; 98: 4599-4604.
5. Ishizuka T, Chayama K, Takeda K, Hamel-mann E, Terada N, Keller GM, Johnson GL, Gelfand EW: Mitogen-activated protein kinase activation through Fcε receptor I and stem cell factor receptor is differentially regulated by phosphatidylinositol 3-kinase and calcineurin in mouse bone marrow-derived mast cells. J Immunol 1999; 162: 2087-2094.
6. Kawakami Y, Nishimoto H, Kitaura J, Mae-da-Yamamoto M, Kato RM, Littman DR, Rawlings DJ, Kawakami T: Protein kinase C βII regulates Akt phosphorylation on ser-473 in a cell type-and stimulus-specific fashion. J Biol Chem 2004; 279: 47720-47725.
7. Kitaura J, Asai K, Maeda-Yamamoto M, Kawakami Y, Kikkawa U, Kawakami T: Akt-dependent cytokine production in mast cells. J Exp Med 2000; 192: 729-739.
8. Marshall JS: Mast-cell responses to pathogens. Nature Rev Immunol 2004; 4: 787-799.
9. Di Nardo A, Vitiello A, Gallo RL: Mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003; 170: 2274-2278.
10. DiNardo A, Yamasaki K, Dorschner RA, Lai Y, Galbo RL: Mast cell cathelicidin antimicrobial peptide prevents immune group A Streptococcus infection of the skin. J Immunol 2008; 180: 7565-7573.
11. Brown KL, Hancock REW: Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 2006; 18: 24-30.
12. Gallo RL, Nizet V: Endogenous production of antimicrobial peptides in innate immunity and human disease. Curr Allergy Asthma Reps 2003; 3: 402-409.
13. Zanetti M: Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2003; 75: 39-48.
14. Niyonsaba F, Ogawa H: Protective roles of the skin against infection: implication of naturally occurring human antimicrobial agents β-defensins, cathelicidin LL-37 and lysozyme. J Dermatol Sci 2005; 40: 157-168.
15. Rodriguez-Martinez S, Cancino-Diaz ME, Cancino-Diaz JC: Expression of CRAMP via PGN-TLR-2 and of α-defensin-3 via CpG-ODN-TLR-9 in corneal fibroblasts. Br J Ophthalmol 2006; 90: 378-382.
16. Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DYM: Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol 2004; 172: 1763-1767.
17. Agerberth B, Charo J, Werr J, Olsson B, Ida- li F, Lindbom L, Kiessling R, Jornvall H, Wigzell H, Gudmundsson GH: The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96: 3086-3093.
18. Niyonsaba F, Iwabuchi K, Someya A, Hira-ta M, Matsuda H, Ogawa H, Nagaoka I: A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 2002; 106: 20-26.
19. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE: The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002; 169: 3883-3891.
20. Braff MH, Hawkins MA, Di Nardo A, Lopez-Garcia B, Howell MD, Wong C, Lin K, Streib JE, Dorschner R, Leung DYM, Gallo RL: Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immu-nostimulatory activities. J Immunol 2005; 174: 4271-4278.
21. Mookherjee N, Brown KL, Bowdish DME, Doria S, Falsafi R, Hokamp K, Roche FM, Mu R, Doho GH, Pistolic J, Powers JP, Bryan J, Brinkman FSL, Hancock REW: Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006; 176: 2455-2464.
22. Tjabringa GS, Aarbiou J, Ninaber DK, Drijf-hout JW, Sorensen OE, Borregaard N, Rabe KF, Hiemstra PS: The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 2003; 171: 6690-6696.
23. Kurosaka K, Chen Q, Yarovinsky F, Oppen-heim JJ, Yang D: Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J Immunol 2005; 174: 6257-6265.
24. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I: Evaluation of the effects of pep-tide antibiotics human beta-defensins-1/2 and LL-37 on histamine release and prosta-glandin D(2) production from mast cells. Eur J Immunol 2001; 31: 1066-1075.
25. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R, Li M, Sato K, Saluja AK, Steer ML, Goldberg AL, Simons M: Inhibition of ubiq-uitin-proteasome pathway-mediated I-B-degradation by a naturally occurring antibacterial peptide. J Clin Invest 2000; 106: 439-448.
26. Masuda A, Yoshikai Y, Aiba K, Matsuguchi T: Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. J Immunol 2002: 169: 3801-3810.
27. Akira S, Takeda K: Toll-like receptor signaling. Nature Rev Immunol 2004; 4: 499-511.
28. Li G, Lucas JJ, Gelfand EW: Protein kinase Cα, βI, and βII isozymes regulate cytokine production in mast cells through MEKK2/ ERK5-dependent and independent pathways. Cell Immunol 2005; 238: 10-18.
29. + T cells to the development of airway hyperresponsiveness and inflammation is associated with IL-13. J Im-munol 2004; 172: 2549-2558.
30. Han KJ, Su X, Xu LG, Bin LH, Zhang J, Shu HB: Mechanisms of the TRIF-induced interferon-stimulated response element and NF-κB activation and apoptosis pathways. J Biol Chem 2004; 279: 15652-15661.
31. Li G, Domenico J, Lucas JJ, Gelfand EW: Identification of multiple cell cycle regulatory functions of p57 Kip2 in human T lymphocytes. J Immunol 2004; 173: 2383-2391.
32. Qureshi ST, Lariviere L, Leveque G, Cler-mont S, Moore KJ, Gros P, Malo D: Endo-toxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999; 189: 615-625.
33. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the lps gene product. J Im-munol 1999; 162: 3749-3752.
34. Viatour P, Merville MP, Bours V, Chariot A: Phosphorylation of NF-κB abd IκBproteins: implications in cancer and inflammation. Trends Biochem Sci 2005; 30: 43-52.
35. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92: 7686-7689.
36. Symons A, Beinke S, Ley SC: MAP kinase ki-nase kinases and innate immunity. Trends Immunol 2006; 27: 40-48.
37. Nagaoka I, Yomogida S, Tamura H, Hirata M: Antibacterial cathelicidin peptide CAP11 inhibits the lipopolysaccharide (LPS)-induced suppression of neutrophil apoptosis by blocking the binding of LPS to target cells. Inflamm Res 2004; 53: 609-622.
38. Stassen M, Muller C, Arnold M, Hultner L, Klein-Hessling S, Neudorfl C, Reineke T, Serfling E, Schmitt E: IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccha-ride: NF-kB is decisively involved in the expression of IL-9. J Immunol 2001; 166: 4391-4398.
39. Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, Ogawa H: Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 2002: 109: 1351-1359.
40. Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Strieb JE, Leung DYM: Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006; 24: 341-348.
41. Hamid QA, Boguniewicz M, Leung DYM: Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94: 870-876.
42. Wei X, Sun R, Fan R, Hahn J, Joetham A, Li G, Webb S, Garrington TP, Dakhama A, Lucas JJ, Johnson GL, Gelfand EW: MEF2C regulates c-Jun but not TNF-α gene expression in stimulated mast cells. Eur J Immunol 2003; 33: 2903-2909.
43. Schauber J, Svanholm C, Termen S, Iffland K, Menzel T, Scheppach W, Melcher R, Ager-berth B, Luhrs H, Gudmundsson GH: Expression of the cathelicidin LL-37 is modu-latedbyshortchainfattyacidsincolonocytes: relevance of signaling pathways. Gut 2003; 52: 735-741.
44. Schwab M, Reynders V, Shastri Y, Loitsch S, Stein J, Schroder O: Role of nuclear hormone receptors in butyrate-mediated up-regulation of the antimicrobial peptide cathelici-din in epithelial colorectal cells. Mol Immu-nol 2007; 44: 2107-2114.
45. Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF: Cell differentiation is a key determinant of cathelicidin LL-37/human cat-ionic antimicrobial protein 18 expression by human colon epithelium. Infect Immun 2002; 70: 953-963.
46. Schauber J, Iffland K, Frisch S, Kudlich T, Schmausser B, Eck M, Menzel T, Gostner A, Luhrs H, Scheppach W: Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol Immunol 2004; 41: 847-854.
47. Sayama K, Komatsuzawa H, Yamasaki K, Shirakata Y, Hanakawa Y, Ouhara K, Toku-maru S, Dai X, Tohyama M, Ten Dijke P, Sugai M, Ichijo H, Hashimoto K: New mechanisms of skin innate immunity: ASK1-mediated keratinocyte differentiation regulates the expression of beta-defensins, LL37 and TLR2. Eur J Immunol 2005; 35: 1886-1895.
48. Méndez-Samperio P, Miranda E, Trejo A: Expression and secretion of cathelicidin LL-37 in human epithelial cells by Mycobacte-rium bovis Bacillus Calmette-Guérin (BCG). Clin Vaccine Immunol 2008; 15: 1450-1455.
49. Place RF, Noonan EJ, Giardina C: HDAC inhibition prevents NF-κB activation by suppressing proteasome activity: down-regulation of proteosome subunit expression stabilizes IκBα. Biochem Pharm 2005; 70: 394-406.
50. Quivy V, Van Lint C: Regulation at multiple levels of NF-κB-mediated transactivation by protein acetylation. Biochem Pharm 2004; 68: 1221-1229.
51. Adam E, Quivy V, Bex F, Chariot A, Collette Y, Vanhulle C, Schoonbroodt S, Goffin V, Nguyen TL, Gloire G, Carrard G, Friguet B, De Launoit Y, Burny A, Bours V, Piette J, Van Lint C: Potentiation of tumor necrosis factor-induced NF-κB activation by deacetylase inhibitors is associated with a delayed cyto-plasmic reappearance of IκBα. Mol Cell Biol 2003; 23: 6200-6209.
52. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003-3007.
53. Buchau AS, Schauber J, Hutsch T, Stuetz A, Gallo RL: Pimecrolimus enhances TLR2/6-induced expression of antimicrobial pep-tides in keratinocytes. J Invest Dermatol 2008; 128: 2646-2654.
54. Kumar A, Yin J, Zhang J, Yu FS: Modulation of corneal epithelial innate immune response to pseudomonas infection by flagel-lin pretreatment. Invest Ophthalmol Vis Sci 2007; 48: 4664-4670.
55. Wehkamp J, Harder J, Wehkamp K, Weh-kamp-von Meissner B, Schlee M, Enders C, Sonneborn U, Nuding S, Bengmark S, Feller-mann K, Schroder JM, Strange EF: NF-kap-paB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Im-mun 2004; 72: 5750-5758.
56. Wehkamp K, Schwichtenberg L, Schroder JM, Harder J: Pseudomonas aeruginosa- and IL-1beta-mediated induction of human beta-defensin-2 in keratinocytes is controlled by NF-kappaB and AP-1. J Invest Dermatol 2006; 126: 121-127.
57. Rivera J, Gilfillan AM: Molecular regulation of mast cell activation. J Allergy Clin Immu-nol 2006; 117: 1214-1225.
58. Orange JS, Levy O, Geha RS: Human disease resulting from gene mutations that interfere with appropriate nuclear factor-κB activation. Immunol Rev 2005; 203: 21-37.